1. | BUYtheWeak | |
2. | johnhoar | |
3. | MamisTrist | |
4. | nlanas2sk051p |
1. | BUYtheWeak | |
2. | johnhoar | |
3. | MamisTrist | |
4. | nlanas2sk051p |
1. | johnhoar 04/03/2018 EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma |
2. | johnhoar 03/10/2018 Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate |
3. | johnhoar 01/30/2018 Great news - Company granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma |
4. | nlanas2sk051p 02/08/2018 Seeing EPS beats reported by $0.63 and by $0.70. Beats on revenues. |
5. | BUYtheWeak 09/12/2017 @MamisTrist Yup, looking like it if you haven't already |
6. | MamisTrist 09/12/2017 Time to buy? |
7. | MamisTrist 03/02/2018 FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma |
8. | BUYtheWeak 01/24/2018 More good news |